Over-the-Counter Monograph User Fees: Reopening of Comment Period; Stakeholder Meeting, 52444-52445 [2016-18717]
Download as PDF
52444
Federal Register / Vol. 81, No. 152 / Monday, August 8, 2016 / Notices
FOR FURTHER INFORMATION CONTACT:
Michael Ryan, Center for Devices and
Radiological Health, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 66, Rm. 1615, Silver Spring,
MD 20993–0002, 301–796–6283,
michael.ryan@fda.hhs.gov; or Stephen
Ripley, Center for Biologics Evaluation
and Research, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 71, Rm. 7301, Silver Spring,
MD 20993–0002, 240–402–7911.
SUPPLEMENTARY INFORMATION:
mstockstill on DSK3G9T082PROD with NOTICES
I. Background
A premarket notification (510(k)) is
required when a legally marketed device
subject to 510(k) requirements is about
to be significantly changed or modified
in design, components, method of
manufacture, or intended use.
Significant changes or modifications are
those that could significantly affect the
safety or effectiveness of the device, or
major changes or modifications in the
intended use of the device (21 CFR
807.81(a)(3)). This guidance, when
finalized, will aid manufacturers of
medical devices who intend to modify
a 510(k)-cleared device or a
preamendments device subject to 510(k)
(i.e., ‘‘existing devices’’) during the
process of deciding whether the
modification exceeds the regulatory
threshold of 21 CFR 807.81(a)(3) for
submission and clearance of a new
510(k).
This guidance, when finalized, will
supersede the original ‘‘Deciding When
to Submit a 510(k) for a Change to an
Existing Device,’’ issued on January 10,
1997. That guidance provided the
Agency’s interpretation of whether the
modification exceeds the regulatory
threshold of 21 CFR 807.81(a)(3), with
principles and points for manufacturers
to consider in analyzing how changes in
devices may affect safety or
effectiveness and determining whether a
new 510(k) must be submitted for a
particular type of change. This draft
guidance preserves the basic format and
content of the original, with updates to
add clarity. The added clarity is
intended to increase consistent
interpretations of the guidance by FDA
staff and manufacturers.
Elsewhere in this issue of the Federal
Register, FDA is announcing the
availability of the guidance document
entitled ‘‘Deciding When to Submit a
510(k) for a Software Change to an
Existing Device’’ to aid manufacturers of
medical devices who intend to make
software changes to an existing device
during the process of deciding whether
the software modification exceeds the
regulatory threshold of 21 CFR
VerDate Sep<11>2014
22:23 Aug 05, 2016
Jkt 238001
807.81(a)(3) for submission and
clearance of a new 510(k).
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
II. Significance of Guidance
This draft guidance is being issued
consistent with FDA’s good guidance
practices regulation (21 CFR 10.115).
The draft guidance, when finalized, will
represent the current thinking of FDA
on when to submit a 510(k) for a change
to an existing device. It does not
establish any rights for any person and
is not binding on FDA or the public.
You can use an alternative approach if
it satisfies the requirements of the
applicable statutes and regulations.
Food and Drug Administration
III. Electronic Access
Persons interested in obtaining a copy
of the draft guidance may do so by
downloading an electronic copy from
the Internet. A search capability for all
Center for Devices and Radiological
Health guidance documents is available
at https://www.fda.gov/MedicalDevices/
DeviceRegulationandGuidance/
GuidanceDocuments/default.htm.
Guidance documents are also available
at https://www.fda.gov/BiologicsBlood
Vaccines/GuidanceCompliance
RegulatoryInformation/default.htm or
https://www.regulations.gov. Persons
unable to download an electronic copy
of ‘‘Deciding When to Submit a 510(k)
for a Change to an Existing Device’’ may
send an email request to CDRHGuidance@fda.hhs.gov to receive an
electronic copy of the document. Please
use the document number 1500054 to
identify the guidance you are
requesting.
IV. Paperwork Reduction Act of 1995
This draft guidance refers to
previously approved collections of
information found in FDA regulations.
These collections of information are
subject to review by the Office of
Management and Budget (OMB) under
the Paperwork Reduction Act of 1995
(44 U.S.C. 3501–3520). The collections
of information in 21 CFR part 820 are
approved under OMB control number
0910–0073; the collections of
information in 21 CFR part 807, subpart
E are approved under OMB control
number 0910–0120; the collections of
information in 21 CFR part 803 have
been approved under OMB control
number 0910–0437; and the collections
of information in 21 CFR parts 801 and
809 are approved under OMB control
number 0910–0485.
Dated: August 2, 2016.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2016–18713 Filed 8–5–16; 8:45 am]
BILLING CODE 4164–01–P
PO 00000
Frm 00048
Fmt 4703
Sfmt 4703
[Docket No. FDA–2016–N–1092]
Over-the-Counter Monograph User
Fees: Reopening of Comment Period;
Stakeholder Meeting
AGENCY:
Food and Drug Administration,
HHS.
Notice of public meeting;
reopening of comment period;
stakeholder meeting.
ACTION:
The Food and Drug
Administration (FDA) is reopening the
comment period for the document that
announced a public meeting in the
Federal Register of May 11, 2016. In the
document, FDA invited public comment
as the Agency considers a user-fee
program for nonprescription (over-thecounter or OTC) monograph drugs. FDA
will hold a Webinar for stakeholders on
September 6, 2016. This Webinar is
intended to be a followup to the June
10, 2016, public meeting on this topic
and to provide stakeholders with a
status update on the process of FDA and
industry discussions that began in July
2016.
DATES: Submit either electronic or
written comments by October 6, 2016.
FDA will hold a Webinar for
stakeholders on Tuesday, September 6,
2016, from 10:30 a.m. to 12 p.m. EDT.
ADDRESSES: You may submit comments
as follows:
SUMMARY:
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal: https://
www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
E:\FR\FM\08AUN1.SGM
08AUN1
Federal Register / Vol. 81, No. 152 / Monday, August 8, 2016 / Notices
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
mstockstill on DSK3G9T082PROD with NOTICES
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand delivery/Courier (for
written/paper submissions): Division of
Dockets Management (HFA–305), Food
and Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Division of Dockets
Management, FDA will post your
comment, as well as any attachments,
except for information submitted,
marked and identified, as confidential,
if submitted as detailed in
‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2016–N–1092 for ‘‘Over-the-Counter
Monograph User Fees: Reopening of
Comment Period; Stakeholder Meeting.’’
Received comments will be placed in
the docket and, except for those
submitted as ‘‘Confidential
Submissions,’’ publicly viewable at
https://www.regulations.gov or at the
Division of Dockets Management
between 9 a.m. and 4 p.m., Monday
through Friday.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ The
Agency will review this copy, including
the claimed confidential information, in
its consideration of comments. The
second copy, which will have the
claimed confidential information
redacted/blacked out, will be available
for public viewing and posted on https://
www.regulations.gov. Submit both
copies to the Division of Dockets
Management. If you do not wish your
name and contact information to be
made publicly available, you can
provide this information on the cover
sheet and not in the body of your
comments and you must identify this
information as ‘‘confidential.’’ Any
information marked as ‘‘confidential’’
will not be disclosed except in
accordance with 21 CFR 10.20 and other
applicable disclosure law. For more
information about FDA’s posting of
comments to public dockets, see 80 FR
56469, September 18, 2015, or access
the information at: https://www.fda.gov/
VerDate Sep<11>2014
22:23 Aug 05, 2016
Jkt 238001
regulatoryinformation/dockets/
default.htm.
Docket: For access to the docket to
read background documents or the
electronic and written/paper comments
received, go to https://
www.regulations.gov and insert the
docket number, found in brackets in the
heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Division of Dockets
Management, 5630 Fishers Lane, Rm.
1061, Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT:
Amy Bertha, Office of Executive
Programs, Center for Drug Evaluation
and Research, Food and Drug
Administration, 10903 New Hampshire
Ave., Silver Spring, MD 20993–0002,
301–796–1647, email:
OTCMonographUserFeeProgram
@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
I. Background
FDA is reopening until October 6,
2016, the comment period for the
document that announced a public
meeting in the Federal Register of May
11, 2016 (81 FR 29275). In the
document, FDA invited public comment
as the Agency considers a user-fee
program for nonprescription (over-thecounter or OTC) monograph drugs. A
user-fee program would provide funding
to supplement congressional non-userfee appropriations, and would support
timely and efficient FDA review of the
efficacy and safety of ingredients
included in or proposed for inclusion in
a monograph. A public meeting on this
topic was held on June 10, 2016, and
interested persons were given until July
11, 2016, to submit comments. To
ensure that all interested persons have
sufficient opportunity to share their
views on a potential OTC monograph
user-fee program, FDA is reopening the
comment period until October 6, 2016.
FDA will hold a Webinar for
stakeholders on September 6, 2016. This
Webinar is intended to be a followup to
the June 10, 2016, public meeting and
provide stakeholders with a status
update on the process of FDA and
industry discussions that began in July
2016. Meeting minutes from these
discussions can be found at: https://
www.fda.gov/omuf. Additional
background information on OTC
monograph drugs (such as how OTC
drugs can be marketed, the differences
between marketing through approved
applications and marketing under the
monographs), factors FDA considers
important in developing a user-fee
program, and the questions FDA asked
the public to consider and provide
PO 00000
Frm 00049
Fmt 4703
Sfmt 4703
52445
input, can be found in the Federal
Register document from the June 10,
2106, public meeting (https://
www.federalregister.gov/articles/2016/
05/11/2016-11098/over-the-countermonograph-user-fees-public-meetingrequest-for-comments). The meeting
transcript, meeting recording, and
presentations from the June 10, 2016,
public meeting, which can serve as
further background information, can be
found at: https://www.fda.gov/Drugs/
NewsEvents/ucm499390.htm.
II. Stakeholder Meeting Participation
FDA is seeking participation at the
Webinar by stakeholders, including
scientific and academic experts, health
care professionals, representatives of
patient and consumer advocacy groups,
and representatives of the OTC
monograph industry. Participating in
the Webinar is free. The Webinar format
will include presentations by FDA staff
and an opportunity for stakeholders to
ask questions. If you wish to attend the
Webinar, FDA asks that you please
register through Eventbrite by Tuesday,
August 30, 2016 (https://
www.eventbrite.com/e/over-the-countermonograph-user-fees-stakeholdermeeting-tickets-26751882601). FDA will
email the registered attendees a URL to
join the Webinar at least 1 day before
the meeting.
Dated August 3, 2016.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2016–18717 Filed 8–5–16; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2015–N–1805]
Retrospective Review of Premarket
Approval Application Devices; Striking
the Balance Between Premarket and
Postmarket Data Collection
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice; request for comments.
The Food and Drug
Administration (FDA) is announcing the
completion of the target of the goal
established to address the Center for
Devices and Radiological Health’s
(CDRH) 2014–2015 Strategic Priority
‘‘Strike the Right Balance Between
Premarket and Postmarket Data
Collection.’’ To achieve this Strategic
Priority, CDRH established a goal to
assure the appropriate balance between
premarket and postmarket data
SUMMARY:
E:\FR\FM\08AUN1.SGM
08AUN1
Agencies
[Federal Register Volume 81, Number 152 (Monday, August 8, 2016)]
[Notices]
[Pages 52444-52445]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-18717]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2016-N-1092]
Over-the-Counter Monograph User Fees: Reopening of Comment
Period; Stakeholder Meeting
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice of public meeting; reopening of comment period;
stakeholder meeting.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is reopening the
comment period for the document that announced a public meeting in the
Federal Register of May 11, 2016. In the document, FDA invited public
comment as the Agency considers a user-fee program for nonprescription
(over-the-counter or OTC) monograph drugs. FDA will hold a Webinar for
stakeholders on September 6, 2016. This Webinar is intended to be a
followup to the June 10, 2016, public meeting on this topic and to
provide stakeholders with a status update on the process of FDA and
industry discussions that began in July 2016.
DATES: Submit either electronic or written comments by October 6, 2016.
FDA will hold a Webinar for stakeholders on Tuesday, September 6, 2016,
from 10:30 a.m. to 12 p.m. EDT.
ADDRESSES: You may submit comments as follows:
Electronic Submissions
Submit electronic comments in the following way:
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to https://www.regulations.gov
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such as a manufacturing process. Please note that if you include your
name, contact information, or other information that identifies you in
the body of your comments, that information will be posted on https://www.regulations.gov.
If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a
[[Page 52445]]
written/paper submission and in the manner detailed (see ``Written/
Paper Submissions'' and ``Instructions'').
Written/Paper Submissions
Submit written/paper submissions as follows:
Mail/Hand delivery/Courier (for written/paper
submissions): Division of Dockets Management (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
For written/paper comments submitted to the Division of
Dockets Management, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
Instructions: All submissions received must include the Docket No.
FDA-2016-N-1092 for ``Over-the-Counter Monograph User Fees: Reopening
of Comment Period; Stakeholder Meeting.'' Received comments will be
placed in the docket and, except for those submitted as ``Confidential
Submissions,'' publicly viewable at https://www.regulations.gov or at
the Division of Dockets Management between 9 a.m. and 4 p.m., Monday
through Friday.
Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will
review this copy, including the claimed confidential information, in
its consideration of comments. The second copy, which will have the
claimed confidential information redacted/blacked out, will be
available for public viewing and posted on https://www.regulations.gov.
Submit both copies to the Division of Dockets Management. If you do not
wish your name and contact information to be made publicly available,
you can provide this information on the cover sheet and not in the body
of your comments and you must identify this information as
``confidential.'' Any information marked as ``confidential'' will not
be disclosed except in accordance with 21 CFR 10.20 and other
applicable disclosure law. For more information about FDA's posting of
comments to public dockets, see 80 FR 56469, September 18, 2015, or
access the information at: https://www.fda.gov/regulatoryinformation/dockets/default.htm.
Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Division of Dockets Management, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT: Amy Bertha, Office of Executive
Programs, Center for Drug Evaluation and Research, Food and Drug
Administration, 10903 New Hampshire Ave., Silver Spring, MD 20993-0002,
301-796-1647, email: OTCMonographUserFeeProgram@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
I. Background
FDA is reopening until October 6, 2016, the comment period for the
document that announced a public meeting in the Federal Register of May
11, 2016 (81 FR 29275). In the document, FDA invited public comment as
the Agency considers a user-fee program for nonprescription (over-the-
counter or OTC) monograph drugs. A user-fee program would provide
funding to supplement congressional non-user-fee appropriations, and
would support timely and efficient FDA review of the efficacy and
safety of ingredients included in or proposed for inclusion in a
monograph. A public meeting on this topic was held on June 10, 2016,
and interested persons were given until July 11, 2016, to submit
comments. To ensure that all interested persons have sufficient
opportunity to share their views on a potential OTC monograph user-fee
program, FDA is reopening the comment period until October 6, 2016.
FDA will hold a Webinar for stakeholders on September 6, 2016. This
Webinar is intended to be a followup to the June 10, 2016, public
meeting and provide stakeholders with a status update on the process of
FDA and industry discussions that began in July 2016. Meeting minutes
from these discussions can be found at: https://www.fda.gov/omuf.
Additional background information on OTC monograph drugs (such as how
OTC drugs can be marketed, the differences between marketing through
approved applications and marketing under the monographs), factors FDA
considers important in developing a user-fee program, and the questions
FDA asked the public to consider and provide input, can be found in the
Federal Register document from the June 10, 2106, public meeting
(https://www.federalregister.gov/articles/2016/05/11/2016-11098/over-the-counter-monograph-user-fees-public-meeting-request-for-comments).
The meeting transcript, meeting recording, and presentations from the
June 10, 2016, public meeting, which can serve as further background
information, can be found at: https://www.fda.gov/Drugs/NewsEvents/ucm499390.htm.
II. Stakeholder Meeting Participation
FDA is seeking participation at the Webinar by stakeholders,
including scientific and academic experts, health care professionals,
representatives of patient and consumer advocacy groups, and
representatives of the OTC monograph industry. Participating in the
Webinar is free. The Webinar format will include presentations by FDA
staff and an opportunity for stakeholders to ask questions. If you wish
to attend the Webinar, FDA asks that you please register through
Eventbrite by Tuesday, August 30, 2016 (https://www.eventbrite.com/e/over-the-counter-monograph-user-fees-stakeholder-meeting-tickets-26751882601). FDA will email the registered attendees a URL to join the
Webinar at least 1 day before the meeting.
Dated August 3, 2016.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2016-18717 Filed 8-5-16; 8:45 am]
BILLING CODE 4164-01-P